Actively Recruiting

Age: 18Years +
All Genders
NCT06269120

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Led by Novo Nordisk A/S · Updated on 2025-12-05

470

Participants Needed

1

Research Sites

78 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment.

CONDITIONS

Official Title

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed consent obtained before any study-related activities.
  • Decision to start oral semaglutide made by patient or legal authorized representative and treating physician based on local label before study inclusion.
  • Adults aged 18 years or older at the time of consent.
  • Diagnosed with type 2 diabetes mellitus.
  • Currently on metformin with or without other oral antidiabetic drugs (DPP4i or SGLT2i) and/or insulin therapy.
  • Available HbA1c value greater than 7.0% within 90 days before or at the treatment initiation visit.
Not Eligible

You will not qualify if you...

  • Previous participation in this study.
  • Treatment with any investigational drug within 30 days before enrollment.
  • Mental incapacity, unwillingness, or language barriers preventing understanding or cooperation.
  • Treatment with GLP1-RA within 90 days before treatment initiation.
  • Diagnosis of type 1 diabetes mellitus.
  • Female who is pregnant, breastfeeding, undergoing fertility treatment, or planning pregnancy during the study.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Siklósi Kórház, Diabetológia

Siklós, Hungary, 7801

Actively Recruiting

Loading map...

Research Team

N

Novo Nordisk

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary | DecenTrialz